This vaccine demonstrated effectiveness in mice and was capable of eliciting NY‐ESO‐1‐specific CD8+ and CD4+ T‐cell responses in cancer patients with pre‐existing NY‐ESO‐1 immunity.89 This evidence concerns the gene CD4 and cancer.